Repression of phosphoinositide-dependent protein kinase 1 expression by ciglitazone via Egr-1 represents a new approach for inhibition of lung cancer cell growth

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Hann, SWei S ^a   Tang, Qing ^a   Zheng, Fang ^a   Zhao, Shunyu ^a   Chen, Jianping ^b   Wang, ZhiYu ^b  

^a GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

^b THE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

AMPK ; Ciglitazone; Egr 1; Human lung adenocarcinoma cell; Metformin; PDK1

Indexed keywords

CASPASE 3; CASPASE 7; CIGLITAZONE; EARLY GROWTH RESPONSE FACTOR 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; STRESS ACTIVATED PROTEIN KINASE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE; EGR1 PROTEIN, HUMAN; PDPK1 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME REPRESSION; GENE ACTIVITY; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MTT ASSAY; PROMOTER REGION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; NON SMALL CELL LUNG CANCER; PATHOLOGY; SIGNAL TRANSDUCTION;

3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASES; AMP-ACTIVATED PROTEIN KINASES; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; EARLY GROWTH RESPONSE PROTEIN 1; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; METFORMIN; PPAR GAMMA; PROMOTER REGIONS, GENETIC; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES;

EID: 84902055951     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-149     Document Type: Article

References (43)

1. Lee CB, Stinchcombe TE, Rosenman JG, Socinski MA. Therapeutic advances in local-regional therapy for stage III non-small-cell lung cancer: evolving role of dose-escalated conformal (3-dimensional) radiation therapy. Clin Lung Cancer 2006, 8:195-202. 10.3816/CLC.2006.n.047, 17239295.
2. Dempke WC, Suto T, Reck M. Targeted therapies for non-small cell lung cancer. Lung Cancer 2010, 67:257-274. 10.1016/j.lungcan.2009.10.012, 19914732.
3. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30. 10.3322/caac.21166, 23335087.
4. Tan NS, Michalik L, Desvergne B, Wahli W. Multiple expression control mechanisms of peroxisome proliferator-activated receptors and their target genes. J Steroid Biochem Mol Biol 2005, 93:99-105. 10.1016/j.jsbmb.2004.12.025, 15860251.
5. Choi JH, Banks AS, Kamenecka TM, Busby SA, Chalmers MJ, Kumar N, Kuruvilla DS, Shin Y, He Y, Bruning JB, Marciano DP, Cameron MD, Laznik D, Jurczak MJ, Schürer SC, Vidović D, Shulman GI, Spiegelman BM, Griffin PR. Antidiabetic actions of a non-agonist PPARgamma ligand blocking Cdk5-mediated phosphorylation. Nature 2011, 477:477-481. 10.1038/nature10383, 3179551, 21892191.
6. Terrasi M, Bazan V, Caruso S, Insalaco L, Amodeo V, Fanale D, Corsini LR, Contaldo C, Mercanti A, Fiorio E, Lo Re G, Cicero G, Surmacz E, Russo A. Effects of PPARgamma agonists on the expression of leptin and vascular endothelial growth factor in breast cancer cells. J Cell Physiol 2013, 228:1368-1374. 10.1002/jcp.24295, 23254958.
7. Li S, Zhou Q, He H, Zhao Y, Liu Z. Peroxisome proliferator-activated receptor gamma agonists induce cell cycle arrest through transcriptional regulation of Kruppel-like factor 4 (KLF4). J Biol Chem 2013, 288:4076-4084. 10.1074/jbc.M111.317487, 3567659, 23275339.
8. Cellurale C, Girnius N, Jiang F, Cavanagh-Kyros J, Lu S, Garlick DS, Mercurio AM, Davis RJ. Role of JNK in mammary gland development and breast cancer. Cancer Res 2012, 72:472-481. 10.1158/0008-5472.CAN-11-1628, 3261359, 22127926.
9. Liang J, Mills GB. AMPK: a contextual oncogene or tumor suppressor?. Cancer Res 2013, 73:2929-2935. 10.1158/0008-5472.CAN-12-3876, 3725287, 23644529.
10. Cho KN, Sukhthankar M, Lee SH, Yoon JH, Baek SJ. Green tea catechin (-)-epicatechin gallate induces tumour suppressor protein ATF3 via EGR-1 activation. Eur J Cancer 2007, 43:2404-2412. 10.1016/j.ejca.2007.07.020, 2174270, 17764926.
11. Gibbs JD, Liebermann DA, Hoffman B. Egr-1 abrogates the E2F-1 block in terminal myeloid differentiation and suppresses leukemia. Oncogene 2008, 27:98-106. 10.1038/sj.onc.1210627, 17599039.
12. Bar-Shavit R, Turm H, Salah Z, Maoz M, Cohen I, Weiss E, Uziely B, Grisaru-Granovsky S. PAR1 plays a role in epithelial malignancies: transcriptional regulation and novel signaling pathway. IUBMB Life 2011, 63:397-402. 10.1002/iub.452, 21557443.
13. Raimondi C, Falasca M. Targeting PDK1 in cancer. Curr Med Chem 2011, 18:2763-2769. 10.2174/092986711796011238, 21568903.
14. Lu Z, Cox-Hipkin MA, Windsor WT, Boyapati A. 3-phosphoinositide-dependent protein kinase-1 regulates proliferation and survival of cancer cells with an activated mitogen-activated protein kinase pathway. Mol Cancer Res 2010, 8:421-432. 10.1158/1541-7786.MCR-09-0179, 20197379.
15. Liu Y, Wang J, Wu M, Wan W, Sun R, Yang D, Sun X, Ma D, Ying G, Zhang N. Down-regulation of 3-phosphoinositide-dependent protein kinase-1 levels inhibits migration and experimental metastasis of human breast cancer cells. Mol Cancer Res 2009, 7:944-954. 10.1158/1541-7786.MCR-08-0368, 19531564.
16. Hann SS, Zheng F, Zhao S. Targeting 3-phosphoinositide-dependent protein kinase 1 by N-acetyl-cysteine through activation of peroxisome proliferators activated receptor alpha in human lung cancer cells, the role of p53 and p65. J Exp Clin Cancer Res 2013, 32:43. 10.1186/1756-9966-32-43, 3720217, 23867003.
17. Gagliardi PA, di Blasio L, Orso F, Seano G, Sessa R, Taverna D, Bussolino F, Primo L. 3-phosphoinositide-dependent kinase 1 controls breast tumor growth in a kinase-dependent but Akt-independent manner. Neoplasia 2012, 14:719-731. 3431179, 22952425.
18. Wu J, Wu JJ, Yang LJ, Wei LX, Zou DJ. Rosiglitazone protects against palmitate-induced pancreatic beta-cell death by activation of autophagy via 5′-AMP-activated protein kinase modulation. Endocrine 2013, 44:87-98. 10.1007/s12020-012-9826-5, 23109223.
19. Morrison A, Yan X, Tong C, Li J. Acute rosiglitazone treatment is cardioprotective against ischemia-reperfusion injury by modulating AMPK, Akt, and JNK signaling in nondiabetic mice. Am J Physiol Heart Circ Physiol 2011, 301:H895-H902. 10.1152/ajpheart.00137.2011, 21666107.
20. Ramer R, Heinemann K, Merkord J, Rohde H, Salamon A, Linnebacher M, Hinz B. COX-2 and PPAR-gamma confer cannabidiol-induced apoptosis of human lung cancer cells. Mol Cancer Ther 2013, 12:69-82.
21. Peifer C, Alessi DR. Small-molecule inhibitors of PDK1. ChemMedChem 2008, 3:1810-1838. 10.1002/cmdc.200800195, 18972468.
22. Plissonnier ML, Fauconnet S, Bittard H, Lascombe I. The antidiabetic drug ciglitazone induces high grade bladder cancer cells apoptosis through the up-regulation of TRAIL. PLoS One 2011, 6:e28354. 10.1371/journal.pone.0028354, 3236187, 22174792.
23. Moss PE, Lyles BE, Stewart LV. The PPARgamma ligand ciglitazone regulates androgen receptor activation differently in androgen-dependent versus androgen-independent human prostate cancer cells. Exp Cell Res 2010, 316:3478-3488. 10.1016/j.yexcr.2010.09.015, 2977976, 20932825.
24. Al-Alem L, Southard RC, Kilgore MW, Curry TE. Specific thiazolidinediones inhibit ovarian cancer cell line proliferation and cause cell cycle arrest in a PPARgamma independent manner. PLoS One 2011, 6:e16179. 10.1371/journal.pone.0016179, 3025024, 21283708.
25. Pestereva E, Kanakasabai S, Bright JJ. PPARgamma agonists regulate the expression of stemness and differentiation genes in brain tumour stem cells. Br J Cancer 2012, 106:1702-1712. 10.1038/bjc.2012.161, 3349185, 22531638.
26. Han S, Roman J. Rosiglitazone suppresses human lung carcinoma cell growth through PPARgamma-dependent and PPARgamma-independent signal pathways. Mol Cancer Ther 2006, 5:430-437. 10.1158/1535-7163.MCT-05-0347, 16505118.
27. Hazra S, Batra RK, Tai HH, Sharma S, Cui X, Dubinett SM. Pioglitazone and rosiglitazone decrease prostaglandin E2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase. Mol Pharmacol 2007, 71:1715-1720. 10.1124/mol.106.033357, 17412838.
28. Yang C, Jo SH, Csernus B, Hyjek E, Liu Y, Chadburn A, Wang YL. Activation of peroxisome proliferator-activated receptor gamma contributes to the survival of T lymphoma cells by affecting cellular metabolism. Am J Pathol 2007, 170:722-732. 10.2353/ajpath.2007.060651, 1851856, 17255338.
29. Wang P, Dharmaraj N, Brayman MJ, Carson DD. Peroxisome proliferator-activated receptor gamma activation inhibits progesterone-stimulated human MUC1 expression. Mol Endocrinol 2010, 24:1368-1379. 10.1210/me.2009-0221, 2903911, 20484415.
30. Han EJ, Im CN, Park SH, Moon EY, Hong SH. Combined treatment with peroxisome proliferator-activated receptor (PPAR) gamma ligands and gamma radiation induces apoptosis by PPARgamma-independent up-regulation of reactive oxygen species-induced deoxyribonucleic acid damage signals in non-small cell lung cancer cells. Int J Radiat Oncol Biol Phys 2013, 85:e239-e248. 10.1016/j.ijrobp.2012.11.040, 23332223.
31. Kim BM, Maeng K, Lee KH, Hong SH. Combined treatment with the Cox-2 inhibitor niflumic acid and PPARgamma ligand ciglitazone induces ER stress/caspase-8-mediated apoptosis in human lung cancer cells. Cancer Lett 2011, 300:134-144. 10.1016/j.canlet.2010.09.014, 21067863.
32. Tsai JS, Chen CY, Chen YL, Chuang LM. Rosiglitazone inhibits monocyte/macrophage adhesion through de novo adiponectin production in human monocytes. J Cell Biochem 2010, 110:1410-1419. 10.1002/jcb.22657, 20506517.
33. Okami N, Narasimhan P, Yoshioka H, Sakata H, Kim GS, Jung JE, Maier CM, Chan PH. Prevention of JNK phosphorylation as a mechanism for rosiglitazone in neuroprotection after transient cerebral ischemia: activation of dual specificity phosphatase. J Cereb Blood Flow Metab 2013, 33:106-114. 10.1038/jcbfm.2012.138, 3597369, 23032483.
34. Awuah PK, Rhieu BH, Singh S, Misse A, Monga SP. beta-Catenin loss in hepatocytes promotes hepatocellular cancer after diethylnitrosamine and phenobarbital administration to mice. PLoS One 2012, 7:e39771. 10.1371/journal.pone.0039771, 3382575, 22761897.
35. Shimoyamada H, Yazawa T, Sato H, Okudela K, Ishii J, Sakaeda M, Kashiwagi K, Suzuki T, Mitsui H, Woo T, Tajiri M, Ohmori T, Ogura T, Masuda M, Oshiro H, Kitamura H. Early growth response-1 induces and enhances vascular endothelial growth factor-A expression in lung cancer cells. Am J Pathol 2010, 177:70-83. 10.2353/ajpath.2010.091164, 2893652, 20489156.
36. Myung DS, Park YL, Kim N, Chung CY, Park HC, Kim JS, Cho SB, Lee WS, Lee JH, Joo YE. Expression of early growth response-1 in colorectal cancer and its relation to tumor cell proliferation and apoptosis. Oncol Rep 2014, 31:788-794.
37. Ma Y, Cheng Q, Ren Z, Xu L, Zhao Y, Sun J, Hu S, Xiao W. Induction of IGF-1R expression by EGR-1 facilitates the growth of prostate cancer cells. Cancer Lett 2012, 317:150-156. 10.1016/j.canlet.2011.11.021, 22115966.
38. Chbicheb S, Yao X, Rodeau JL, Salamone S, Boisbrun M, Thiel G, Spohn D, Grillier-Vuissoz I, Chapleur Y, Flament S, Mazerbourg S. EGR1 expression: a calcium and ERK1/2 mediated PPARgamma-independent event involved in the antiproliferative effect of 15-deoxy-Delta12,14-prostaglandin J2 and thiazolidinediones in breast cancer cells. Biochem Pharmacol 2011, 81:1087-1097. 10.1016/j.bcp.2011.02.006, 21338579.
39. Di-Poi N, Tan NS, Michalik L, Wahli W, Desvergne B. Antiapoptotic role of PPARbeta in keratinocytes via transcriptional control of the Akt1 signaling pathway. Mol Cell 2002, 10:721-733. 10.1016/S1097-2765(02)00646-9, 12419217.
40. Kim JB, Wright HM, Wright M, Spiegelman BM. ADD1/SREBP1 activates PPARgamma through the production of endogenous ligand. Proc Natl Acad Sci U S A 1998, 95:4333-4337. 10.1073/pnas.95.8.4333, 22489, 9539737.
41. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010, 468:968-972. 10.1038/nature09627, 3058384, 21107320.
42. Moon Y, Bottone FG, McEntee MF, Eling TE. Suppression of tumor cell invasion by cyclooxygenase inhibitors is mediated by thrombospondin-1 via the early growth response gene Egr-1. Mol Cancer Ther 2005, 4:1551-1558. 10.1158/1535-7163.MCT-05-0213, 16227405.
43. Zheng Y, Ritzenthaler JD, Sun X, Roman J, Han S. Prostaglandin E2 stimulates human lung carcinoma cell growth through induction of integrin-linked kinase: the involvement of EP4 and Sp1. Cancer Res 2009, 69:896-904. 10.1158/0008-5472.CAN-08-2677, 19176380.